Clinical Trial Update: A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating high-dose ursodeoxycholic acid (18-22 mg/kg/day) in patients with refractory primary biliary cholangitis; current status is no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Ursodeoxycholic acid (ursodeoxycholic acid)

Snippet

Sponsor: West China Hospital | Conditions: Primary Biliary Cholangitis | Phase 4 | Status: UNKNOWN